Microneedle and mucosal delivery of influenza vaccines

Expert Review of Vaccines

Volumn 11, Issue 5, 2012, Pages 547-560

  Kang, Sang Moo ^a   Song, Jae Min ^a,b   Kim, Yeu Chun ^c  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Sungshin Women's University   (South Korea)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

influenza vaccine; microneedles; mucosal immunization; skin vaccination

Indexed keywords

INFLUENZA VACCINE;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SELF ADMINISTRATION; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VACCINATION; INTERMETHOD COMPARISON; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MATERIAL COATING; MICROINJECTION; MICRONEEDLE; NEEDLE; NONHUMAN; ORAL DRUG ADMINISTRATION; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; TRANSDERMAL PATCH;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANIMALS; HUMANS; IMMUNITY, MUCOSAL; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; MICE; MICROINJECTIONS; MIDDLE AGED; NEEDLES; VACCINATION; YOUNG ADULT;

EID: 84862512975     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.25     Document Type: Review

References (154)

1. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur. Respir. J. 17(6), 1282-1293 (2001
2. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171(10), 4969-4973 (2003
3. Plotkin SA. Vaccines: past, present and future. Nat. Med. 11(4 Suppl.), S5-S11 (2005
4. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull. World Health Organ. 77(10), 801-807 (1999
5. Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot. Int. 19(1), 95-103 (2004
6. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations. Am. J. Trop. Med. Hyg. 68(3), 341-344 (2003
7. Breau LM, McGrath PJ, Craig KD, Santor D, Cassidy KL, Reid GJ. Facial expression of children receiving immunizations: a principal components analysis of the child facial coding system. Clin. J. Pain 17(2), 178-186 (2001
8. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26(26), 3197-3208 (2008
9. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998
10. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4(3), 211-222 (2004
11. McKenzie R, Bourgeois AL, Frech SA et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebocontrolled challenge study. Vaccine 25(18), 3684-3691 (2007
12. Skountzou I, Quan FS, Jacob J, Compans RW, Kang SM. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 24(35-36), 6110-6119 (2006
13. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6(12), 1403-1406 (2000
14. Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, Weber F. Acceptance of Intanza® 9g intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv. Ther. 28(8), 640-649 (2011
15. Belshe RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 103(1-2), 177-185 (2004
16. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369-393 (2009
17. Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotechnol. 26(11), 1261-1268 (2008
18. Birchall J, Coulman S, Pearton M et al. Cutaneous DNA delivery and gene expression in ex vivo human skin explants via wet-etch micro-fabricated microneedles. J. Drug Target. 13(7), 415-421 (2005
19. Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J. Control. Release 104(1), 51-66 (2005
20. Pearton M, Allender C, Brain K et al. Gene delivery to the epidermal cells of human skin explants using microfabricated microneedles and hydrogel formulations. Pharm. Res. 25(2), 407-416 (2008
21. Dean CH, Alarcon JB, Waterston AM et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Hum. Vaccin. 1(3), 106-111 (2005
22. Mikszta JA, Dekker JP 3rd, Harvey NG et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun. 74(12), 6806-6810 (2006
23. Prausnitz MR. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 56(5), 581-587 (2004
24. Widera G, Johnson J, Kim L et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 24(10), 1653-1664 (2006
25. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J. Control. Release 117(2), 227-237 (2007
26. Gill HS, Prausnitz MR. Coating formulations for microneedles. Pharm. Res. 24(7), 1369-1380 (2007
27. Pearton M, Kang SM, Song JM et al. Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines. PLoS ONE 5(8), e12410 (2010
28. Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25(10), 1814-1823 (2007
29. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials 29(13), 2113-2124 (2008
30. Park JH, Allen MG, Prausnitz MR. Polymer microneedles for controlled-release drug delivery. Pharm. Res. 23(5), 1008-1019 (2006
31. SulliVan SP, Koutsonanos DG, Del Pilar Martin M et al. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16(8), 915-920 (2010
32. Birchall JC. Microneedle array technology: the time is right but is the science ready? Expert Rev. Med. Devices 3(1), 1-4 (2006
33. Donnelly RF, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv. 17(4), 187-207 (2010
34. Alarcon JB, Hartley AW, Harvey NG, Mikszta JA. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin. Vaccine Immunol. 14(4), 375-381 (2007
35. Atmar RL, Patel SM, Keitel WA. Intanza®: a new intradermal vaccine for seasonal influenza. Expert Rev. Vaccines 9(12), 1399-1409 (2010
36. Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25(52), 8833-8842 (2007
37. Laurent PE, Pettis R, Easterbrook W, Berube J. Evaluating new hypodermic and intradermal injection devices. Med. Device Technol. 17(2), 16-19 (2006
38. Duggan ST, Plosker GL. Intanza 15 microg intradermal seasonal influenza vaccine: in older adults (aged or =60 years). Drugs Aging 27(7), 597-605 (2010
39. Falsey AR. New emerging technologies and the intradermal route: the novel way to immunize against influenza. Vaccine 28(Suppl. 4), D24-D32 (2010
40. Beran J, Ambrozaitis A, Laiskonis A et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med. 7, 13 (2009
41. Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198(5), 650-658 (2008
42. Coudeville L, Andre P, Bailleux F, Weber F, Plotkin S. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum. Vaccin. 6(10), 841-848 (2010
43. Arnou R, Icardi G, De Decker M et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter Phase III study. Vaccine 27(52), 7304-7312 (2009
44. Van Damme P, Arnou R, Kafeja F et al. Evaluation of noninferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect. Dis. 10, 134 (2010
45. McElhaney JE, Dutz JP. Better influenza vaccines for older people: what will it take? J. Infect. Dis. 198(5), 632-634 (2008
46. Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 119(6), 1076-1082 (2007
47. Laurent A, Mistretta F, Bottigioli D et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 25(34), 6423-6430 (2007
48. Belshe RB, Newman FK, Wilkins K et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25(37-38), 6755-6763 (2007
49. Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin. Infect. Dis. 50(10), 1331-1338 (2010
50. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27(3), 454-459 (2009
51. Sugimura T, Ito Y, Tananari Y et al. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Vaccine 26(22), 2700-2705 (2008
52. Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 25(4), 659-663 (2007
53. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med. 351(22), 2295-2301 (2004
54. La Montagne JR, Fauci AS. Intradermal influenza vaccination - can less be more? N. Engl. J. Med. 351(22), 2330-2332 (2004
55. Langley JM. Intradermal injection of reduced-dose influenza vaccine was immunogenic in young adults. ACP J. Club 142(3), 68-69 (2005
56. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev. Vaccines 7(8), 1201-1214 (2008
57. Zhu Q, Zarnitsyn VG, Ye L et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc. Natl Acad. Sci. USA 106(19), 7968-7973 (2009
58. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 27(49), 6932-6938 (2009
59. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS ONE 4(3), e4773 (2009
60. Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS ONE 4(9), e7152 (2009
61. Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 25(6), 1256-1273 (2008
62. Quan FS, Kim YC, Compans RW, Prausnitz MR, Kang SM. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J. Control. Release 147(3), 326-332 (2010
63. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech 11(3), 1193-1201 (2010
64. Song JM, Kim YC, Barlow PG et al. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res. 88(2), 244-247 (2010
65. Quan FS, Kim YC, Vunnava A et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J. Virol. 84(15), 7760-7769 (2010
66. Song JM, Kim YC, Lipatov AS et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin. Vaccine Immunol. 17(9), 1381-1389 (2010
67. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG et al. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J. Infect. Dis. 204(4), 582-591 (2011
68. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J. Infect. Dis. 201(2), 190-198 (2010
69. De Becker G, Sornasse T, Nabavi N et al. Immunoglobulin isotype regulation by antigen-presenting cells in vivo. Eur. J. Immunol. 24(7), 1523-1528 (1994
70. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113(7), 998-1007 (2004
71. Guebre-Xabier M, Hammond SA, Epperson DE, Yu J, Ellingsworth L, Glenn GM. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J. Virol. 77(9), 5218-5225 (2003
72. Hon H, Jacob J. Tracking dendritic cells in vivo: insights into DC biology and function. Immunol. Res. 29(1-3), 69-80 (2004
73. Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res. 143(2), 140-146 (2009
74. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J. Control. Release 142(2), 187-195 (2010
75. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm. Res. 28(1), 135-144 (2011
76. Maa YF, Ameri M, Shu C, Payne LG, Chen D. Influenza vaccine powder formulation development: spray-freezedrying and stability evaluation. J. Pharm. Sci. 93(7), 1912-1923 (2004
77. Amorij JP, Meulenaar J, Hinrichs WL et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25(35), 6447-6457 (2007
78. Chen D, Endres RL, Erickson CA et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat. Med. 6(10), 1187-1190 (2000
79. Chen D, Weis KF, Chu Q et al. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J. Virol. 75(23), 11630-11640 (2001
80. Chen D, Periwal SB, Larrivee K et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J. Virol. 75(17), 7956-7965 (2001
81. Dean HJ, Chen D. Epidermal powder immunization against influenza. Vaccine 23(5), 681-686 (2004
82. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148-158 (2006
83. Brandtzaeg P, Baekkevold ES, Farstad IN et al. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol. Today 20(3), 141-151 (1999
84. Modlin JF, Onorato IM, McBean AM et al. The humoral immune response to type 1 oral poliovirus vaccine in children previously immunized with enhanced potency inactivated poliovirus vaccine or live oral poliovirus vaccine. Am. J. Dis. Child. 144(4), 480-484 (1990
85. Levine MM, Hone D, Tacket C, Ferreccio C, Cryz S. Clinical and field trials with attenuated Salmonella typhi as live oral vaccines and as "carrier" vaccines. Res. Microbiol. 141(7-8), 807-816 (1990
86. Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 8, 129 (2010
87. Chandran A, Santosham M. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine. Expert Rev. Vaccines 7(10), 1475-1480 (2008
88. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338(20), 1405-1412 (1998
89. Kagnoff MF, Eckmann L. Epithelial cells as sensors for microbial infection. J. Clin. Invest. 100(1), 6-10 (1997
90. Izadpanah A, Dwinell MB, Eckmann L, Varki NM, Kagnoff MF. Regulated MIP-3alpha/CCL20 production by human intestinal epithelium: mechanism for modulating mucosal immunity. Am. J. Physiol. Gastrointest. Liver Physiol. 280(4), G710-G719 (2001
91. Fooks AR. Development of oral vaccines for human use. Curr. Opin. Mol. Ther. 2(1), 80-86 (2000
92. des Rieux A, Fievez V, Momtaz M et al. Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium. J. Control. Release 118(3), 294-302 (2007
93. Lazzell V, Waldman RH, Rose C, Khakoo R, Jacknowitz A, Howard S. Immunization against influenza in humans using an oral enteric-coated killed virus vaccine. J. Biol. Stand. 12(3), 315-321 (1984
94. Bergmann KC, Waldman RH, Tischner H, Pohl WD. Antibody in tears, saliva and nasal secretions following oral immunization of humans with inactivated influenza virus vaccine. Int. Arch. Allergy Appl. Immunol. 80(1), 107-109 (1986
95. Bergmann KC, Waldman RH. Oral immunization with influenza virus: experimental and clinical studies. Curr. Top. Microbiol. Immunol. 146, 83-89 (1989
96. Avtushenko SS, Sorokin EM, Zoschenkova NY, Zacharova NG, Naichin AN. Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization. J. Biotechnol. 44(1-3), 21-28 (1996
97. Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27(27), 3643-3649 (2009
98. Pang GT, Clancy RL, O'Reilly SE, Cripps AW. A novel particulate influenza vaccine induces long-term and broad-based immunity in mice after oral immunization. J. Virol. 66(2), 1162-1170 (1992
99. Takase H, Murakami Y, Endo A, Ikeuchi T. Antibody responses and protection in mice immunized orally against influenza virus. Vaccine 14(17-18), 1651-1656 (1996
100. Ghazi HO, Potter CW, Smith TL, Jennings R. Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs. J. Med. Microbiol. 42(1), 53-61 (1995
101. Lei H, Xu Y, Chen J, Wei X, Lam DM. Immunoprotection against influenza H5N1 virus by oral administration of entericcoated recombinant Lactococcus lactis mini-capsules. Virology 407(2), 319-324 (2010
102. Van Daal GJ, Beusenberg FD, So KL et al. Protection against influenza A virus infection in mice by oral immunization with a polyvalent bacterial lysate. Int. J. Immunopharmacol. 13(7), 831-840 (1991
103. Amorij JP, Westra TA, Hinrichs WL, Huckriede A, Frijlink HW. Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model. Vaccine 26(1), 67-76 (2007
104. McGhee JR, Yamamoto M, Kang DW et al. Isotype of anti-SIV responses in infected rhesus macaques and in animals immunized by mucosal routes. AIDS Res. Hum. Retroviruses 8(8), 1389 (1992
105. Waldman RH, Bergmann KC, Stone J et al. Age-dependent antibody response in mice and humans following oral influenza immunization. J. Clin. Immunol. 7(4), 327-332 (1987
106. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21(23), 3212-3218 (2003
107. Wang BZ, Xu R, Quan FS, Kang SM, Wang L, Compans RW. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS ONE 5(11), e13972 (2010
108. Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75(11), 5141-5150 (2001
109. Perrone LA, Ahmad A, Veguilla V et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 83(11), 5726-5734 (2009
110. Quan FS, Compans RW, Kang SM. Oral vaccination with inactivated influenza vaccine induces cross-protective immunity. Vaccine 30(2), 180-188 (2012
111. Renegar KB, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 173(3), 1978-1986 (2004
112. Quan FS, Compans RW, Nguyen HH, Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82(3), 1350-1359 (2008
113. Mazanec MB, Lamm ME, Lyn D, Portner A, Nedrud JG. Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. Virus Res. 23(1-2), 1-12 (1992
114. Liew FY, Russell SM, Appleyard G, Brand CM, Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur. J. Immunol. 14(4), 350-356 (1984
115. Alsharifi M, Furuya Y, Bowden TR et al. Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS ONE 4(4), e5336 (2009
116. Waldman RH, Mann JJ, Small PA Jr. Immunization against influenza. Prevention of illness in man by aerosolized inactivated vaccine. JAMA 207(3), 520-524 (1969
117. Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18(22), 2416-2425 (2000
118. Boyce TG, Hsu HH, Sannella EC et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19(2-3), 217-226 (2000
119. Ichinohe T, Watanabe I, Ito S et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79(5), 2910-2919 (2005
120. Pal S, Luke CJ, Barbour AG, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine 21(13-14), 1455-1465 (2003
121. Peppoloni S, Ruggiero P, Contorni M et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2(2), 285-293 (2003
122. Jertborn M, Nordström I, Kilander A, Czerkinsky C, Holmgren J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect. Immun. 69(6), 4125-4128 (2001
123. Wassén L, Schön K, Holmgren J, Jertborn M, Lycke N. Local intravaginal vaccination of the female genital tract. Scand. J. Immunol. 44(4), 408-414 (1996
124. Glück R, Mischler R, Durrer P et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181(3), 1129-1132 (2000
125. Gluck R. Review of intranasal influenza vaccine. Adv. Drug Deliv. Rev. 51(1-3), 203-211 (2001
126. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350(9), 896-903 (2004
127. Dhere R, Yeolekar L, Kulkarni P et al. A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine 29(Suppl. 1), A16-A21 (2011
128. Xie H, Liu TM, Lu X et al. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/ Vietnam/1203/2004, in mice. J. Infect. Dis. 200(12), 1874-1883 (2009
129. Suguitan AL Jr, McAuliffe J, Mills KL et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad crossprotection in mice and ferrets. PLoS Med. 3(9), e360 (2006
130. Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr. Infect. Dis. J. 23(2), 138-144 (2004
131. Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 30(5), 886-892 (2012
132. Beyer WE, Palache AM, de Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20(9-10), 1340-1353 (2002
133. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 71(12), 1591-1622 (2011)
134. Fiore AE, Uyeki TM, Broder K et al.; CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. Recomm. Rep. 59(RR-8), 1-62 (2010
135. Treanor J, Nolan C, O'Brien D et al. Intranasal administration of a proteosomeinfluenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24(3), 254-262 (2006
136. Plante M, Jones T, Allard F et al. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine 20(1-2), 218-225 (2001
137. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11(4 Suppl.), S45-S53 (2005
138. Lambrecht BN, Prins JB, Hoogsteden HC. Lung dendritic cells and host immunity to infection. Eur. Respir. J. 18(4), 692-704 (2001
139. Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM. Mucosal immunity: implications for vaccine development. Immunobiology 184(2-3), 157-179 (1992
140. Waldman RH, Wood SH, Torres EJ, Small PA Jr. Influenza antibody response following aerosal administration of inactivated virus. Am. J. Epidemiol. 91(6), 574-585 (1970
141. Waldman RH, Bond JO, Levitt LP et al. An evaluation of influenza immunization: influence of route of administration and vaccine strain. Bull. World Health Organ. 41(3), 543-548 (1969
142. Wee JL, Scheerlinck JP, Snibson KJ et al. Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. Mucosal Immunol. 1(6), 489-496 (2008
143. Vujanic A, Snibson KJ, Wee JL et al. Long-term antibody and immune memory response induced by pulmonary delivery of influenza Iscomatrix vaccine. Clin. Vaccine Immunol. 19(1), 79-83 (2011
144. Vujanic A, Wee JL, Snibson KJ et al. Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens. Vaccine 28(14), 2593-2597 (2010
145. Minne A, Louahed J, Mehauden S, Baras B, Renauld JC, Vanbever R. The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology 122(3), 316-325 (2007
146. Smith JH, Nagy T, Barber J, Brooks P, Tompkins SM, Tripp RA. Aerosol inoculation with a sub-lethal influenza virus leads to exacerbated morbidity and pulmonary disease pathogenesis. Viral Immunol. 24(2), 131-142 (2011
147. Pena L, Vincent AL, Ye J et al. Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses. J. Virol. 85(1), 456-469 (2011
148. Quan FS, Yoo DG, Song JM, Clements JD, Compans RW, Kang SM. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J. Virol. 83(9), 4489-4497 (2009
149. Weldon WC, Martin MP, Zarnitsyn V et al. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin. Vaccine Immunol. 18(4), 647-654 (2011
150. D'Souza B, Bhowmik T, Shashidharamurthy R, Oettinger C, Selvaraj P, D'Souza M. Oral microparticulate vaccine for melanoma using M-cell targeting. J. Drug Target. 20(2), 166-173 (2012
151. Lidbury BA, Grissell TV, Sizer PJ, Pang GT, Clancy R, Cripps AW. Erythrocytes enhance the immunogenicity of oral vaccination with gamma irradiated influenza virus: increasing the dose of irradiation results in a significant diminution of lung IgA response. Vaccine 15(14), 1529-1537 (1997
152. Sendi P, Locher R, Bucheli B, Battegay M. Intranasal influenza vaccine in a working population. Clin. Infect. Dis. 38(7), 974-980 (2004
153. Sendi P, Locher R, Bucheli B, Battegay M. The decision to get vaccinated against influenza. Am. J. Med. 116(12), 856-858 (2004
154. Kunkel EJ, Campbell DJ, Butcher EC. Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation 10(3-4), 313-323 (2003